Axonal cytoskeletal changes in experimental glaucoma
Axonal cytoskeletal changes in experimental glaucoma
批准号:
8321570
负责人:
BRAD FORTUNE
金额:
$32.72万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2013-11-30
关键词:
AnimalsAxonBiopsy SpecimenBirefringenceBlindnessCaliberCell DeathCell physiologyChronicChronic DiseaseClinicalDataData AnalysesData CollectionDetectionDiagnosisEarly DiagnosisElectroretinographyExperimental ModelsEyeFunctional disorderGlaucomaHistologicIndividualLasersMeasurementMeasuresMicrotubulesOptic DiskOptic NerveOptical Coherence TomographyOpticsPatientsPhasePhysiologic Intraocular PressurePropertyRetinaRetinalRetinal Ganglion CellsScanningStagingStaining methodStainsStructureSurfaceTestingTherapeuticTherapeutic InterventionThickTrabecular meshwork structureTransmission Electron MicroscopyUnited Statesabstractingbasecell injuryclinical caredesignfunctional lossin vivolaser photocoagulationnonhuman primatepolarimetrypolarized lightprospectiveresearch studyretinal nerve fiber layertomographytool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract:
This project proposes that prior to retinal ganglion cell (RGC) death in glaucoma, and before permanent loss of
vision, there exists a stage of RGC dysfunction characterized by degradation of axonal microtubules (MTs).
Emerging evidence suggests that MT degradation can occur initially without substantial changes in axonal
caliber. Therefore, it is proposed that early stage RGC dysfunction involving MT degradation should be
preferentially detectable by scanning laser polarimetry (SLP) of the retinal nerve fiber layer (RNFL) prior to
changes in RNFL thickness. This is because the fundamental optical principle of SLP is based on detecting
phase retardance of polarized light, which is due to the optical property birefringence produced in the RNFL by
the long, thin cylindrical MTs. Preliminary studies demonstrate that RNFL retardance declines prior to, and
faster than RNFL thickness in several different experimental models of RGC injury, including experimental
glaucoma (EG). Clinical detection of axonal MT disruption by SLP, in the absence of RNFL thickness changes,
might represent an early and potentially reversible phase of glaucomatous damage and provide a clinically
detectable marker for therapeutic adjustment. Thus the central hypothesis of this proposal is that disruption
of MTs within the axons of the peripapillary RNFL is an early indicator of glaucomatous damage, preceding
both changes in axonal caliber and physical loss of those axons. Predictions arising from this hypothesis are
tested in three Specific Aims using a non-human primate (NHP) model of EG. Specific Aim 1: To test the
prediction that peripapillary RNFL retardance will decline prior to RNFL thickness changes measured by
spectral domain optical coherence tomography (sd-OCT) and prior to optic nerve head (ONH) surface changes
measured by confocal scanning laser tomography (CSLT) in NHP eyes with EG; Specific Aim 2: To test the
predictions that histological evidence of peripapillary RNFL MT disruption will be more pronounced than
histologically-defined RNFL thickness changes and retrobulbar optic nerve axon loss; Specific Aim 3: To test
the prediction that RGC functional abnormalities are associated with the intermediate stage of RGC
degeneration characterized by abnormal axonal MTs. To achieve these Aims, EG will be induced via laser
photocoagulation of the trabecular meshwork to cause moderate, unilateral chronic IOP elevation in 24 NHPs.
Weekly measurements of peripapillary RNFL retardance, RNFL thickness and ONH surface topography will be
made in both eyes of each NHP using SLP, sd-OCT and CSLT, respectively, during a 4-week pre-laser
baseline period and for up to 8 months after onset of EG (Aim 1). For each parameter, statistically significant
change is defined as any change exceeding the baseline intersession variability for each individual eye, twice
confirmed. Once each animal progresses to its endpoint, it is sacrificed for histological data collection and
analysis (Aim 2). During each week of in vivo structural testing for Aim 1, RGC function will also be assessed in
both eyes using three proven forms of electroretinography (Aim 3).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Retinal circuit disassembly in primate glaucoma
-
批准号:10639949
-
项目类别:
-
资助金额:$75.61万
-
财政年份:2023
-
负责人:BRAD FORTUNE
-
依托单位:
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma
-
批准号:10875042
-
项目类别:
-
资助金额:$9.34万
-
财政年份:2021
-
负责人:BRAD FORTUNE
-
依托单位:
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma
-
批准号:10330206
-
项目类别:
-
资助金额:$139.36万
-
财政年份:2021
-
负责人:BRAD FORTUNE
-
依托单位:
Advancing OCT evaluation to reveal early-stage changes in glaucoma
-
批准号:10004040
-
项目类别:
-
资助金额:$54.34万
-
财政年份:2019
-
负责人:BRAD FORTUNE
-
依托单位:
Advancing OCT evaluation to reveal early-stage changes in glaucoma
-
批准号:10228613
-
项目类别:
-
资助金额:$53.03万
-
财政年份:2019
-
负责人:BRAD FORTUNE
-
依托单位:
Advancing OCT evaluation to reveal early-stage changes in glaucoma
-
批准号:10457862
-
项目类别:
-
资助金额:$52.95万
-
财政年份:2019
-
负责人:BRAD FORTUNE
-
依托单位:
Advancing OCT evaluation to reveal early-stage changes in glaucoma
-
批准号:9803604
-
项目类别:
-
资助金额:$56.89万
-
财政年份:2019
-
负责人:BRAD FORTUNE
-
依托单位:
Imaging retinal astrocytes, ganglion cells and axonal transport in vivo
-
批准号:8114960
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2011
-
负责人:BRAD FORTUNE
-
依托单位:
Imaging retinal astrocytes, ganglion cells and axonal transport in vivo
-
批准号:8306681
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2011
-
负责人:BRAD FORTUNE
-
依托单位:
Axonal cytoskeletal changes in experimental glaucoma
-
批准号:7921993
-
项目类别:
-
资助金额:$34.08万
-
财政年份:2009
-
负责人:BRAD FORTUNE
-
依托单位:
Axonal cytoskeletal changes in experimental glaucoma
-
批准号:8129511
-
项目类别:
-
资助金额:$32.72万
-
财政年份:2009
-
负责人:BRAD FORTUNE
-
依托单位:
Axonal cytoskeletal changes in experimental glaucoma
-
批准号:8762356
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2009
-
负责人:BRAD FORTUNE
-
依托单位:
Axonal cytoskeletal changes in experimental glaucoma
-
批准号:7730618
-
项目类别:
-
资助金额:$34.43万
-
财政年份:2009
-
负责人:BRAD FORTUNE
-
依托单位:
海外基金